New Delhi [India], August 6: Welcure Drugs & Pharmaceuticals Ltd (BSE: 524661), today announced its financial results for the quarter ended June 30, 2025 (Q1FY26). The company has reported a robust financial performance in the first quarter of FY26, driven by its strategic foray into fee-based, export-oriented sourcing services.
Welcure’s revenue from operations rose sharply to Rs 299.91 crore in Q1FY26, up from Rs 21.21 crore in the previous quarter (Q4FY25), making it a rise of about 1,300 per cent on a quarter-on-quarter basis. The company reported a net profit of Rs 23.29 crore in Q1FY26 as against a net loss of Rs 0.34 crore in the same period last year (Q1FY25). The company reported a rise of almost 830 per cent in net profit on QoQ basis over a net profit of Rs 2.5 crore in Q4FY25 that ended on March 31, 2025.
Earnings per share (EPS) stood at Rs 2.07 in Q1FY26 as compared to Re -0.26 in Q1FY25.
Speaking about the stellar financial performance of Q1FY26, the management of the company commented, “The strong financial performance in Q1FY26, is a reflection of our business strategies, meticulous decisions and our focused transition to a fee-based, asset-light model. We are committed to sustaining this performance through efficient supply chain management and product diversification.”
The company has recently completed seven export-sourcing assignments totalling Rs 299.91 crore, acting solely as a procurement agent on behalf of international buyers. The company earns a fixed 5 per cent commission on these transactions, with no exposure to inventory, logistics, or working capital risks, preserving its debt-free structure. This shift toward fee-based export services has significantly enhanced Welcure’s revenue profile, with commission income recognized in accordance with Ind AS 115 on a receipt basis.
Additionally, Welcure had earlier secured a major Rs 517 crore global sourcing mandate from Thailand-based Fortune Sagar Impex Company Limited, expected to contribute an estimated Rs 25.85 crore in service income during FY26.
The company implemented important leadership decisions to streamline governance for robust growth. The company appointed Mr Rabi Thakor as an Additional Non-Executive Non-Independent Director. The company also appointed Yogeshkumar Prajapati and Bhumika Pradhan joined as Additional Independent Directors.
About Welcure Drugs & Pharmaceuticals Ltd:
Incorporated in 1992, Welcure Drugs & Pharmaceuticals Ltd is an established pharmaceutical company in India, engaged in the manufacture and trade of a wide range of healthcare formulations. With a focus on quality, compliance, and global integration, Welcure continues to expand its presence in both domestic and international markets.
Highlights:
|
This article is from the Brand Desk. User discretion is advised.
